Optogenetic Vision Restoration
Optogenetic Vision Restoration
批准号:
9769029
负责人:
John Gerard Flannery
金额:
$39.25万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2022-08-31
关键词:
AffectAgeAmericanAnimalsAutomobile DrivingBehaviorBehavioralBlindnessBrainCategoriesCell DeathCellsCharacteristicsChemicalsChoroideremiaClinicComplementComplexConeCuesDataDiseaseEngineeringEyeEye diseasesFDA approvedFormulationG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGlutamate ReceptorGoalsGogglesHeadImageInheritedInjectionsInterneuronsKineticsLightMedicalMotionMusMutationNatural regenerationNeuronsOpsinOutcomeOutputPatientsPatternPattern RecognitionPerformancePhotophobiaPhotoreceptorsPlug-inPopulationPropertyProteinsResearchResolutionRetinaRetinalRetinal DegenerationRetinal DiseasesRetinitis PigmentosaRiskS-nitro-N-acetylpenicillamineScheduleShockSignal TransductionSpeedSystemTestingTherapeuticTimeVertebrate PhotoreceptorsVirusVisionVisualVisual AcuityWild Type Mousebasecombinatorialdesignexperimental studyfootganglion cellgene therapyimprovedinherited retinal degenerationintravitreal injectionlight intensitymicrobialnovel strategiesobject recognitionoptical sensoroptogeneticsphotoreceptor degenerationpreferenceprogramsreceptorreconstitutionrelating to nervous systemresponserestorationretinal neuronretinal prosthesisretinal rodssensorsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Over 100,000 Americans of all ages suffer from inherited retinal diseases (IRD), which cause a progressive loss of vision. In most IRDs, disease begins in the rods, causing vision loss from the periphery to the center, leaving patients unable to navigate their surroundings. Electronic retinal prosthesis restore useful vision in patients affected by IRDs, and optogenetics is an alternative therapeutic. A major limitation of microbial opsins for restoration of retinal light sensitivity is the high light intensity required for activating channelrhodopsins. A solution to this caveat is the use of opsins with higher light sensitivity but sufficiently fast kinetics for useful motion vision.
We propose a novel approach to restore vision to patients using a virus to express a light sensitive
protein in specific, second-order retina neurons to make them light sensitive. Our approach uses a common
neuronal receptor, modified to add a light receptive function to the remaining light-insensitive retinal
neurons that survive after photoreceptor degeneration. The receptor uses either retinal, which is available
in the eye, or a synthetic chemical photoswitch delivered by intravitreal injection. In this way, the cells in
which the receptor is located respond to light with a change in neural firing. This compensates for their loss
of input from photoreceptors, restoring light responsiveness to the retina and sending information to the
brain to restore vision. In most cases, this approach is independent of the mutation that caused the
photoreceptor degeneration. Exceptions to this approach may be diseases that cause RPE cell death, such
as choroideremia.
To date, versions of this approach, developed by Co-PIs Isacoff and Flannery, and others in the
field, have employed receptors that are rather insensitive to light or very slow in response and so could not
support normal vision. We now propose a new strategy that uses the natural amplification properties of
GPCR signaling to increase sensitivity (by 1000 times) and speed. GPCR signaling cascades are intrinsic
to rods and cones, as well as bipolar, ganglion cells and other cells in the retina. We also pursue a new
discovery, emerging from our preliminary experiments, which enables a combinatorial approach that uses
more than one optical sensor molecule at a time in order to recreate the natural diversity of natural
signaling in the retina that had earlier been missing. Finally, we employ sophisticated behavioral analysis to
test not only the restoration of the ability to tell light from dark or flashing from steady light, but to determine
if the animal is able to see images. Success of this program would represent a major step in the creation of
a retinal prosthetic based on gene therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optogenetic Vision Restoration
-
批准号:10247536
-
项目类别:
-
资助金额:$38.07万
-
财政年份:2018
-
负责人:John Gerard Flannery
-
依托单位:
Optogenetic Vision Restoration
-
批准号:10004654
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2018
-
负责人:John Gerard Flannery
-
依托单位:
Directed Evolution of Adeno-Associated Virus for Retinal Gene Therapy
-
批准号:8698194
-
项目类别:
-
资助金额:$48.56万
-
财政年份:2014
-
负责人:John Gerard Flannery
-
依托单位:
Directed Evolution of Adeno-Associated Virus for Retinal Gene Therapy
-
批准号:9130224
-
项目类别:
-
资助金额:$41.07万
-
财政年份:2014
-
负责人:John Gerard Flannery
-
依托单位:
Directed Evolution of Adeno-Associated Virus for Retinal Gene Therapy
-
批准号:8843869
-
项目类别:
-
资助金额:$41.14万
-
财政年份:2014
-
负责人:John Gerard Flannery
-
依托单位:
Directed Evolution of Adeno-Associated Virus for Retinal Gene Therapy
-
批准号:9310291
-
项目类别:
-
资助金额:$40.85万
-
财政年份:2014
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6898152
-
项目类别:
-
资助金额:$36.95万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6518734
-
项目类别:
-
资助金额:$36.19万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6751520
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6359726
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6649517
-
项目类别:
-
资助金额:$42.57万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
Viral Mediated Gene Therapy for Retinal Diseases
-
批准号:6635742
-
项目类别:
-
资助金额:$51.72万
-
财政年份:2001
-
负责人:John Gerard Flannery
-
依托单位:
PHENOTYPIC EXPRESSION IN INHERITED RETINAL DEGENERATIONS
-
批准号:2162616
-
项目类别:
-
资助金额:$11.19万
-
财政年份:1992
-
负责人:John Gerard Flannery
-
依托单位:
PHENOTYPIC EXPRESSION IN INHERITED RETINAL DEGENERATIONS
-
批准号:3266347
-
项目类别:
-
资助金额:$12.28万
-
财政年份:1992
-
负责人:John Gerard Flannery
-
依托单位:
PHENOTYPIC EXPRESSION IN INHERITED RETINAL DEGENERATIONS
-
批准号:2162615
-
项目类别:
-
资助金额:$4.08万
-
财政年份:1992
-
负责人:John Gerard Flannery
-
依托单位:
PHENOTYPIC EXPRESSION IN INHERITED RETINAL DEGENERATIONS
-
批准号:3266348
-
项目类别:
-
资助金额:$6.63万
-
财政年份:1992
-
负责人:John Gerard Flannery
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: